Form 8-K - Current report:
SEC Accession No. 0001193125-26-222818
Filing Date
2026-05-14
Accepted
2026-05-14 07:36:49
Documents
11
Period of Report
2026-05-14
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K pyxs-20260514.htm   iXBRL 8-K 45896
2 EX-99.1 pyxs-ex99_1.htm EX-99.1 216688
3 GRAPHIC img244827169_0.jpg GRAPHIC 46807
  Complete submission text file 0001193125-26-222818.txt   446555

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20260514.xsd EX-101.SCH 25999
14 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20260514_htm.xml XML 4914
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 26975873
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)